Skip to content

Released Mar 13, 2020, before the open

10-K filed Mar 13, 2020, 73 days after period end · 0001104659-20-032764

Q4 2019 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$0.00derived— vs Q4 2018−100.0% vs Q3 2019
Net Income-$3.29MderivedN/M vs Q4 2018N/M vs Q3 2019
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$3,448,251N/M
Operating Cash Flowderived-$3,308,042N/M

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2019derived from reported figuresQ4 2018Q4 2017Q4 2016
Revenue$0.00$0.00$0.00—
Net Income-$3.29M-$3.23M-$5.33M-$2.97M
EPS Diluted—-$0.15-$0.25-$0.16

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Lipocine Inc. · CIK 1535955 · Engraved from SEC EDGAR